Treat Prostate Cancer in Older Men?
Study Suggests Treatment Has Survival Advantage Over 'Watchful Waiting'
Dec. 12, 2006 -- To treat or not to treat? That is the question for older men with early-stage prostate cancer.
The jury is still out, but new research suggests a survival advantage for older prostate cancer patients with localized disease who chose active treatment over close observation without treatment, known as watchful waiting.
The look-back study included data from nearly 45,000 patients between the ages of 65 and 80 with low- to intermediate-risk prostate cancer.
Over 12 years of follow-up, patients treated with either surgery or radiation were found to have a 31% lower risk of death than patients who did not opt for treatment.
The National Institutes of Health-funded trial is published in the Dec. 13 issue of The Journal of the American Medical Association.
"Our findings suggest that there may be a [survival] benefit associated with treating older patients with early-stage disease," researcher Yu-Ning Wong, MD, of Philadelphia’s Fox Chase Cancer Center, tells WebMD.
"While treatment is clearly not the right decision for every patient, the potential for a survival advantage should enter into the decision making."
The latest findings appear to contradict a large Scandinavian trial, published last year, which directly compared prostate cancer surgery to watchful waiting. In that trial, the treatment-related survival advantage was largely confined to men under the age of 65.
Two other large trials directly comparing treatment to nontreatment are under way, one in the U.S. and the other in the U.K. Results from these trials are expected before the end of the decade.
UCLA urology and public health professor Mark S. Litwin, MD, MPH, says these trials should help clarify the issue of who needs treatment and who doesn’t.
He tells WebMD that the study by Wong and colleagues, while very well done, falls short of proving that older prostate cancer patients derive a survival advantage with treatment.
This study should not be seen as a foot on the accelerator for the treatment of these patients, he says. "It is provocative and encouraging. But at the end of the day it is still an observational study, and the ultimate answer has to come from randomized, control trials."